Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Combined Chemotherapy Protocols | 46 | 2022 | 2532 | 2.600 |
Why?
|
Colorectal Neoplasms | 14 | 2022 | 966 | 1.750 |
Why?
|
Angiogenesis Inhibitors | 8 | 2014 | 313 | 1.260 |
Why?
|
Antibodies, Monoclonal | 11 | 2017 | 1401 | 1.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 21 | 2021 | 956 | 0.930 |
Why?
|
Bevacizumab | 19 | 2022 | 286 | 0.850 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 157 | 0.800 |
Why?
|
Disease-Free Survival | 22 | 2022 | 1212 | 0.730 |
Why?
|
Lung Neoplasms | 12 | 2014 | 2332 | 0.730 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2014 | 1107 | 0.670 |
Why?
|
Fluorouracil | 24 | 2022 | 559 | 0.630 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2022 | 1093 | 0.550 |
Why?
|
Neoplasm Metastasis | 15 | 2017 | 1095 | 0.530 |
Why?
|
Leucovorin | 15 | 2022 | 222 | 0.530 |
Why?
|
Indazoles | 2 | 2012 | 67 | 0.520 |
Why?
|
Aged | 53 | 2019 | 18878 | 0.520 |
Why?
|
Middle Aged | 61 | 2022 | 25612 | 0.500 |
Why?
|
Imidazoles | 2 | 2012 | 151 | 0.500 |
Why?
|
Pancreatic Neoplasms | 7 | 2019 | 659 | 0.490 |
Why?
|
Maximum Tolerated Dose | 10 | 2019 | 272 | 0.480 |
Why?
|
Paclitaxel | 8 | 2019 | 477 | 0.460 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 25 | 0.460 |
Why?
|
Carcinoma, Large Cell | 2 | 2011 | 39 | 0.450 |
Why?
|
Head and Neck Neoplasms | 12 | 2022 | 1057 | 0.450 |
Why?
|
Registries | 2 | 2016 | 752 | 0.440 |
Why?
|
Aged, 80 and over | 25 | 2019 | 6704 | 0.400 |
Why?
|
Survival Rate | 15 | 2019 | 1881 | 0.390 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2014 | 421 | 0.390 |
Why?
|
Treatment Outcome | 21 | 2019 | 8136 | 0.390 |
Why?
|
Indoles | 7 | 2014 | 309 | 0.370 |
Why?
|
Pyrroles | 6 | 2014 | 185 | 0.370 |
Why?
|
Adult | 45 | 2019 | 26266 | 0.360 |
Why?
|
Female | 59 | 2022 | 45621 | 0.350 |
Why?
|
Male | 53 | 2022 | 41896 | 0.340 |
Why?
|
Deoxycytidine | 7 | 2019 | 238 | 0.340 |
Why?
|
Liver Neoplasms | 3 | 2019 | 769 | 0.340 |
Why?
|
Carcinoma, Lobular | 1 | 2009 | 81 | 0.330 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2009 | 158 | 0.310 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2019 | 110 | 0.310 |
Why?
|
Adenocarcinoma | 7 | 2011 | 1184 | 0.310 |
Why?
|
Glucuronosyltransferase | 2 | 2019 | 185 | 0.310 |
Why?
|
Salvage Therapy | 2 | 2019 | 235 | 0.300 |
Why?
|
Humans | 70 | 2022 | 88365 | 0.300 |
Why?
|
Colonic Neoplasms | 4 | 2022 | 565 | 0.290 |
Why?
|
ErbB Receptors | 7 | 2014 | 496 | 0.290 |
Why?
|
Bone Neoplasms | 1 | 2009 | 331 | 0.290 |
Why?
|
Antineoplastic Agents | 10 | 2022 | 2402 | 0.280 |
Why?
|
Organoplatinum Compounds | 7 | 2017 | 96 | 0.270 |
Why?
|
Disease Progression | 10 | 2018 | 1488 | 0.270 |
Why?
|
Camptothecin | 5 | 2022 | 191 | 0.260 |
Why?
|
Quinazolines | 4 | 2012 | 221 | 0.260 |
Why?
|
Prognosis | 11 | 2019 | 3746 | 0.250 |
Why?
|
Carboplatin | 5 | 2012 | 302 | 0.240 |
Why?
|
Breast Neoplasms | 7 | 2014 | 2974 | 0.230 |
Why?
|
Cohort Studies | 7 | 2014 | 2833 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2018 | 1349 | 0.220 |
Why?
|
Quinolines | 2 | 2019 | 91 | 0.200 |
Why?
|
Neoplasm Staging | 12 | 2015 | 1978 | 0.190 |
Why?
|
Rectal Neoplasms | 1 | 2022 | 127 | 0.190 |
Why?
|
Pyrazoles | 2 | 2019 | 149 | 0.190 |
Why?
|
Intestinal Perforation | 2 | 2012 | 35 | 0.190 |
Why?
|
Prospective Studies | 7 | 2022 | 4263 | 0.180 |
Why?
|
Cisplatin | 11 | 2012 | 615 | 0.180 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2018 | 262 | 0.170 |
Why?
|
Thromboembolism | 2 | 2010 | 119 | 0.170 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2019 | 45 | 0.170 |
Why?
|
Sulfonamides | 4 | 2021 | 318 | 0.160 |
Why?
|
Protein Kinase Inhibitors | 3 | 2012 | 602 | 0.160 |
Why?
|
Androstenes | 1 | 2018 | 43 | 0.150 |
Why?
|
Food | 1 | 2018 | 86 | 0.150 |
Why?
|
Pyridines | 2 | 2019 | 316 | 0.150 |
Why?
|
Survival Analysis | 6 | 2019 | 1542 | 0.140 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 283 | 0.140 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 96 | 0.140 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2017 | 112 | 0.140 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 119 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2019 | 1943 | 0.140 |
Why?
|
Young Adult | 5 | 2016 | 6179 | 0.130 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 824 | 0.130 |
Why?
|
Proportional Hazards Models | 4 | 2014 | 858 | 0.130 |
Why?
|
Anilides | 1 | 2015 | 48 | 0.130 |
Why?
|
Hedgehog Proteins | 1 | 2015 | 97 | 0.130 |
Why?
|
Chromosome Aberrations | 1 | 2016 | 390 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 861 | 0.120 |
Why?
|
Drug Administration Schedule | 6 | 2019 | 902 | 0.120 |
Why?
|
Biomarkers, Tumor | 6 | 2019 | 1519 | 0.120 |
Why?
|
Disease Management | 1 | 2016 | 328 | 0.120 |
Why?
|
Methotrexate | 6 | 1992 | 250 | 0.120 |
Why?
|
Hypertension | 2 | 2010 | 730 | 0.120 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 4 | 0.120 |
Why?
|
MicroRNAs | 1 | 2019 | 551 | 0.120 |
Why?
|
Follow-Up Studies | 5 | 2019 | 3655 | 0.120 |
Why?
|
Neoplasms | 4 | 2014 | 2995 | 0.110 |
Why?
|
Exanthema | 1 | 2014 | 38 | 0.110 |
Why?
|
Blood Proteins | 1 | 2014 | 145 | 0.110 |
Why?
|
Pilot Projects | 4 | 2017 | 860 | 0.110 |
Why?
|
Proteomics | 1 | 2014 | 227 | 0.100 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.100 |
Why?
|
Adolescent | 10 | 2014 | 9138 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2016 | 597 | 0.100 |
Why?
|
Time Factors | 6 | 2014 | 5302 | 0.100 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 172 | 0.090 |
Why?
|
Bendamustine Hydrochloride | 2 | 2021 | 11 | 0.090 |
Why?
|
Combined Modality Therapy | 7 | 2008 | 1710 | 0.090 |
Why?
|
Alkaline Phosphatase | 1 | 2010 | 133 | 0.090 |
Why?
|
Statistics as Topic | 1 | 2011 | 235 | 0.090 |
Why?
|
Diabetes Complications | 2 | 2010 | 172 | 0.090 |
Why?
|
Arthritis, Rheumatoid | 1 | 1991 | 167 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2012 | 836 | 0.090 |
Why?
|
Lymphoma | 1 | 1991 | 264 | 0.090 |
Why?
|
Rituximab | 2 | 2021 | 119 | 0.090 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 2 | 2021 | 88 | 0.090 |
Why?
|
Tissue Distribution | 1 | 2009 | 292 | 0.090 |
Why?
|
Safety | 1 | 2010 | 151 | 0.080 |
Why?
|
Everolimus | 2 | 2022 | 41 | 0.080 |
Why?
|
Signal Transduction | 2 | 2018 | 3360 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2009 | 498 | 0.080 |
Why?
|
Double-Blind Method | 3 | 2019 | 1713 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2009 | 200 | 0.080 |
Why?
|
Skin Diseases | 1 | 2009 | 173 | 0.080 |
Why?
|
Prostatic Neoplasms | 2 | 2011 | 1763 | 0.070 |
Why?
|
Hemorrhage | 1 | 2009 | 275 | 0.070 |
Why?
|
Carcinoma | 1 | 2010 | 441 | 0.070 |
Why?
|
Precision Medicine | 1 | 2011 | 407 | 0.070 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2006 | 41 | 0.070 |
Why?
|
Taxoids | 3 | 2012 | 130 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2014 | 994 | 0.070 |
Why?
|
Prostate-Specific Antigen | 3 | 2018 | 358 | 0.070 |
Why?
|
Erlotinib Hydrochloride | 3 | 2011 | 90 | 0.070 |
Why?
|
Dacarbazine | 1 | 2006 | 102 | 0.060 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2004 | 38 | 0.060 |
Why?
|
Prednisone | 2 | 2018 | 258 | 0.060 |
Why?
|
Amifostine | 1 | 2004 | 51 | 0.060 |
Why?
|
Drug Eruptions | 1 | 2004 | 34 | 0.060 |
Why?
|
Radiation-Protective Agents | 1 | 2004 | 98 | 0.060 |
Why?
|
Thionucleotides | 1 | 2004 | 56 | 0.060 |
Why?
|
Carcinoma, Small Cell | 1 | 2004 | 133 | 0.060 |
Why?
|
Capecitabine | 2 | 2014 | 98 | 0.050 |
Why?
|
Sex Factors | 2 | 2019 | 1061 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 196 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2018 | 611 | 0.050 |
Why?
|
Age Factors | 2 | 2019 | 1857 | 0.050 |
Why?
|
Remission Induction | 6 | 2008 | 734 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2006 | 774 | 0.040 |
Why?
|
Genotype | 2 | 2019 | 1867 | 0.040 |
Why?
|
Etoposide | 3 | 2008 | 198 | 0.040 |
Why?
|
Stomach Neoplasms | 2 | 2019 | 269 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2013 | 1043 | 0.040 |
Why?
|
Albumins | 1 | 2019 | 130 | 0.040 |
Why?
|
Azetidines | 1 | 2019 | 37 | 0.040 |
Why?
|
Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.040 |
Why?
|
Chemotherapy-Induced Febrile Neutropenia | 1 | 2018 | 6 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 114 | 0.040 |
Why?
|
United States | 4 | 2018 | 6867 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2022 | 686 | 0.040 |
Why?
|
Singapore | 1 | 2018 | 16 | 0.040 |
Why?
|
Radiotherapy, Conformal | 1 | 1999 | 84 | 0.040 |
Why?
|
Placebos | 1 | 2018 | 213 | 0.040 |
Why?
|
Dehydroepiandrosterone | 1 | 2018 | 51 | 0.040 |
Why?
|
Piperidines | 1 | 2019 | 163 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 57 | 0.040 |
Why?
|
Fasting | 1 | 2018 | 163 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1998 | 87 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 215 | 0.040 |
Why?
|
Transforming Growth Factor beta | 1 | 2018 | 321 | 0.030 |
Why?
|
Testosterone | 1 | 2018 | 275 | 0.030 |
Why?
|
Neoplasms, Squamous Cell | 1 | 1996 | 20 | 0.030 |
Why?
|
Postoperative Care | 1 | 2017 | 230 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2019 | 383 | 0.030 |
Why?
|
Technetium | 1 | 1995 | 29 | 0.030 |
Why?
|
Radioimmunodetection | 1 | 1995 | 13 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 477 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2015 | 40 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2018 | 359 | 0.030 |
Why?
|
Drug Therapy, Combination | 5 | 2011 | 798 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2017 | 365 | 0.030 |
Why?
|
Preoperative Care | 1 | 2017 | 399 | 0.030 |
Why?
|
Interferon-alpha | 4 | 1998 | 235 | 0.030 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 1995 | 82 | 0.030 |
Why?
|
Lymphoma, B-Cell | 1 | 1995 | 105 | 0.030 |
Why?
|
Neuropilin-2 | 1 | 2014 | 2 | 0.030 |
Why?
|
Neuropilin-1 | 1 | 2014 | 15 | 0.030 |
Why?
|
Trastuzumab | 1 | 2014 | 69 | 0.030 |
Why?
|
Pemetrexed | 1 | 2014 | 76 | 0.030 |
Why?
|
Glutamates | 1 | 2014 | 89 | 0.030 |
Why?
|
Recombinant Proteins | 4 | 1998 | 1020 | 0.030 |
Why?
|
Odds Ratio | 1 | 2015 | 685 | 0.030 |
Why?
|
Cetuximab | 1 | 2014 | 113 | 0.030 |
Why?
|
Caspase 3 | 1 | 2013 | 161 | 0.030 |
Why?
|
Anemia, Sideroblastic | 1 | 1993 | 7 | 0.030 |
Why?
|
Inflammation | 1 | 2019 | 957 | 0.030 |
Why?
|
Guanine | 1 | 2014 | 208 | 0.030 |
Why?
|
Sirolimus | 1 | 2014 | 173 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 237 | 0.030 |
Why?
|
Zinc | 1 | 1993 | 93 | 0.030 |
Why?
|
Risk Factors | 2 | 2014 | 5435 | 0.030 |
Why?
|
Fatigue | 1 | 2013 | 178 | 0.030 |
Why?
|
Peritoneal Neoplasms | 2 | 2005 | 181 | 0.030 |
Why?
|
Regression Analysis | 2 | 2009 | 594 | 0.020 |
Why?
|
Chromosomal Instability | 1 | 2011 | 19 | 0.020 |
Why?
|
Ploidies | 1 | 2011 | 41 | 0.020 |
Why?
|
Risk Assessment | 1 | 2019 | 2285 | 0.020 |
Why?
|
Loss of Heterozygosity | 1 | 2011 | 86 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2011 | 71 | 0.020 |
Why?
|
ras Proteins | 1 | 2011 | 130 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 164 | 0.020 |
Why?
|
Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
Depression | 1 | 2013 | 494 | 0.020 |
Why?
|
Chicago | 1 | 2014 | 1407 | 0.020 |
Why?
|
Transforming Growth Factor alpha | 1 | 2009 | 50 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 1704 | 0.020 |
Why?
|
Demography | 1 | 2009 | 181 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 84 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 994 | 0.020 |
Why?
|
Mutation | 2 | 2011 | 4092 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 1993 | 408 | 0.020 |
Why?
|
Gene Amplification | 1 | 2008 | 133 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2014 | 2002 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2010 | 770 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 531 | 0.020 |
Why?
|
Exons | 1 | 2009 | 452 | 0.020 |
Why?
|
Piperazines | 1 | 2009 | 280 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2008 | 354 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 1999 | 471 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 661 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2010 | 358 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 928 | 0.020 |
Why?
|
Biomarkers | 1 | 2014 | 1754 | 0.020 |
Why?
|
Hydroxyurea | 2 | 1998 | 239 | 0.020 |
Why?
|
Ketoconazole | 1 | 2006 | 26 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 645 | 0.020 |
Why?
|
Receptors, Estrogen | 3 | 1983 | 386 | 0.020 |
Why?
|
Bleomycin | 2 | 1990 | 102 | 0.020 |
Why?
|
Mitoxantrone | 1 | 2006 | 68 | 0.020 |
Why?
|
Vincristine | 2 | 1983 | 112 | 0.020 |
Why?
|
Models, Molecular | 1 | 2009 | 1294 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2019 | 8852 | 0.020 |
Why?
|
Erythema Multiforme | 1 | 2004 | 4 | 0.020 |
Why?
|
Blister | 1 | 2004 | 8 | 0.020 |
Why?
|
Quality of Life | 1 | 2013 | 1646 | 0.020 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2004 | 22 | 0.020 |
Why?
|
Radiometry | 1 | 2004 | 56 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 2004 | 68 | 0.010 |
Why?
|
Stereoisomerism | 2 | 1996 | 102 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 1841 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 1857 | 0.010 |
Why?
|
Mice | 1 | 2015 | 11685 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 2004 | 1142 | 0.010 |
Why?
|
Melphalan | 1 | 1981 | 98 | 0.010 |
Why?
|
Ascites | 1 | 1981 | 58 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2008 | 2586 | 0.010 |
Why?
|
Incidence | 1 | 2004 | 1588 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2009 | 2633 | 0.010 |
Why?
|
Levoleucovorin | 1 | 1998 | 3 | 0.010 |
Why?
|
Pleural Neoplasms | 1 | 1981 | 196 | 0.010 |
Why?
|
Femoral Nerve | 1 | 1998 | 8 | 0.010 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 1998 | 19 | 0.010 |
Why?
|
Acute Kidney Injury | 1 | 1982 | 307 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1998 | 295 | 0.010 |
Why?
|
Child, Preschool | 1 | 2004 | 3673 | 0.010 |
Why?
|
Administration, Oral | 1 | 1999 | 684 | 0.010 |
Why?
|
Tetrahydrofolates | 1 | 1996 | 13 | 0.010 |
Why?
|
Gallium Radioisotopes | 1 | 1995 | 31 | 0.010 |
Why?
|
Animals | 1 | 2015 | 27134 | 0.010 |
Why?
|
Patient Selection | 1 | 1999 | 689 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1995 | 330 | 0.010 |
Why?
|
Blood Cell Count | 1 | 1993 | 79 | 0.010 |
Why?
|
Child | 1 | 2004 | 7082 | 0.010 |
Why?
|
Iron | 1 | 1993 | 166 | 0.010 |
Why?
|
Cyclophosphamide | 2 | 1983 | 300 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1992 | 138 | 0.010 |
Why?
|
Blood Transfusion | 1 | 1993 | 164 | 0.010 |
Why?
|
Bone Marrow | 1 | 1993 | 442 | 0.010 |
Why?
|
Probability | 2 | 1982 | 356 | 0.010 |
Why?
|
Doxorubicin | 2 | 1983 | 298 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 1990 | 430 | 0.010 |
Why?
|
Pyrimidines | 1 | 1992 | 372 | 0.010 |
Why?
|
Tamoxifen | 1 | 1983 | 168 | 0.000 |
Why?
|
Carcinoembryonic Antigen | 1 | 1981 | 42 | 0.000 |
Why?
|
Menopause | 1 | 1982 | 75 | 0.000 |
Why?
|
Magnesium | 1 | 1982 | 177 | 0.000 |
Why?
|
Axilla | 1 | 1982 | 102 | 0.000 |
Why?
|
Amino Acids | 1 | 1982 | 252 | 0.000 |
Why?
|
Lymph Node Excision | 1 | 1983 | 220 | 0.000 |
Why?
|
Pleural Effusion | 1 | 1981 | 47 | 0.000 |
Why?
|
Radiotherapy | 1 | 1983 | 331 | 0.000 |
Why?
|
Mastectomy | 1 | 1983 | 243 | 0.000 |
Why?
|
Mitomycins | 1 | 1979 | 13 | 0.000 |
Why?
|
Fever | 1 | 1981 | 127 | 0.000 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 53 | 0.000 |
Why?
|
Calcium | 1 | 1982 | 1170 | 0.000 |
Why?
|